The Trump administration's Food and Drug Administration (FDA) has implemented new, looser regulations for vaping products and nicotine pouches, which is expected to lead to hundreds more of these products entering the market in the coming weeks and months. This shift allows products to be sold without undergoing the prior requirement of full scientific authorization from the agency, a move that critics warn could pose significant public health risks, particularly given the addictive nature of nicotine.
This policy change followed a meeting between President Trump and tobacco executives, during which the conversation specifically addressed nicotine pouches. Reportedly, Trump took an interest in the product and expressed a desire for more of these pouches to be authorized. This meeting was seen as a significant boon for the booming nicotine pouch market. A subsidiary of Reynolds American also made a $5 million contribution to a pro-Trump super PAC prior to this meeting.
The decision blindsided senior officials within the FDA's tobacco center, with some staffers learning of the new guidelines only the night before their publication. These officials were not consulted on the changes, which break with the FDA's longstanding policy requiring scientific verification of health benefits for smokers before new products are introduced. Former FDA Commissioner Marty Makary, who had clashed with the White House over such approvals, resigned days after these guidelines were posted.
President Trump had previously criticized Makary for slow approvals of flavored vapes and nicotine products. The administration's push to accelerate these approvals came after tobacco industry lobbying efforts. While critics express concerns about increased addiction and health effects, some experts argue that adults need alternatives to traditional tobacco products. The move is widely seen as a victory for "Big Tobacco" and aligns with their long-standing lobbying efforts.
